NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Revenue

Biotechnology Research • Haifa, Haifa District, Israel • 21-50 Employees

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) revenue & valuation

Annual revenue	$2,224,430
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$7,200,000
Total funding	$4,554,300

Key Contacts at NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

Lior Shaltiel

Chief Executive Officer

Tali Kizhner

Rd Director

Company overview

Headquarters	Haifa, Haifa District, Israel
Website	nurexone.com
NAICS	541714
Founded	2020
Employees	21-50
Socials

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Email Formats

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) uses 2 email formats. The most common is {first name} (e.g., john@nurexone.com), used 70.4% of the time.

Format	Example	Percentage
{first name}	john@nurexone.com	70.4%
{first initial}	j@nurexone.com	29.6%

About NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Head

Senior

Employees by Department

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) has 13 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)'s funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2023-11-11	9	$252,700
2024-10-26	14	$1,300,000
2025-02-21	14	$839,300
2025-05-04	14	$1,600,000
2025-09-20	14	$562,300

Funding Insights

$4,554,300

Total funding amount

$562,300

Most recent funding amount

Number of funding rounds

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Tech Stack

Discover the technologies and tools that power NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)'s digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

Security

Site Kit

Analytics

jQuery UI

JavaScript libraries

Hello Elementor

WordPress themes

Elementor

Page builders

jQuery Migrate

JavaScript libraries

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

MailChimp

Google Analytics

Analytics

Frequently asked questions

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) is located in Haifa, Haifa District, IL.

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) generates an estimated annual revenue of $2,224,430. This revenue figure reflects the company's market position and business performance in its industry.

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) has an estimated valuation of $7,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) was founded in 2020, making it 6 years old. The company has established itself as a significant player in its industry over this time.

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) has raised a total of $4,554,300 across 5 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

Lior Shaltiel

Chief Executive Officer

Tali Kizhner

Rd Director

4.8

40,000 users